Kendle International, Inc. (KNDL)

Screened. Looks worth a shot.

Good fundamentals

porte pitch

Following translator999 with this one.
See the excellent pitch by portefeuille.

I seen this type of graph before. It's getting ready to go skyward.

All this medical attention is looking in the wrong place. Along comes a kendle and changes the landscape. We should see huge earning improvements for the rest of 2009 and expansion into 2010. go small caps!!!!!

Cheap.

Considering Book value, earnings, and market cap...this should beat the market in 5 years.

With Kendle in turn around mode, this stock is poised to be much higher over the next 2-4 years.

The falling dollar, which barring any millitary action, should bennefit Kendle's bottom line, since the derive about 50% of their earnings over seas.

Also, Kendle has a very healthy balance sheet to weather a short term downturn in the economy.

Kendle should also bennefit from the continued outsourcing of drug testing. I am also assuming that in the next few years several of your teir 2 research firms will get together to challenge Covance who is the largest research firm in the sector. I think Kendle will be a likely party.

Jump on board while this one is on sale.

yes

If anything bio pharmaceutical research is going to increase in the future, for both social (long term aging of population) and political (short term, aka Obama) reasons. Kendle is incredibly undervalued right now. I'm surprised Warren hasn't stepped in and bought the whole thing. I'm going to beat him to it.

Selection made on the movement toward more pharma outsourcing.

Low relative PE, good star ranking, PEG & 09 PE still below normal - bottom fishing.

Pharma outsourcing will benefit CROs in the long run.

Drug companies are desperate to cut costs. Outsourcing drug testing to KNDL is an excellent way for them to save money.

TM's Clinical Trial Outsourcer Basket

Although the biopharmaceutical services industry looks strong going forward, KNDL has a lower ROE (5.5%) than I'm happy with. Their decision to take on $198 million in debt in 2006 is worrying. This move raised their current liabilities to a level where they would need to make 8 times as much cash from operations just to keep up. Their EPS might be going up but their balance sheet is paying the price. Many companies make this mistake and end up digging the hole the market buries them in.

Its rated 4 stars on CAPS, but your time would be better spent on a bio services company with a higher ROE and lower debt ratios.

Underperform!

StockFecther.com - Stoch research (Why:Above sma 50 with a stochastic reverse.)